EGFR and cancer: In this overview, we summarized recent studies on the application of PD-1/PD-L1 ICIs in EGFR-mutant NSCLC, mapped the cancer-immunity cycle of individual patients, and tried to explore the potential mechanisms leading to the poor clinical efficacy of ICIs in EGFR-mutant NSCLC, providing ideas for the development of specific immunotherapy or immunotherapy combinations.